A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide

A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide

Purpose: The survival times of glioblastoma (GB) patients after the standard therapy including safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide are heterogeneous. In order to define a simple, reliable method for predicting whether patients with isocitrate de...

Full description

Bibliographic Details
Main Authors: Anne Clavreul, Jean-Michel Lemée, Gwénaëlle Soulard, Audrey Rousseau, Philippe Menei
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
glioblastoma
hematological markers
survival
prognosis
Online Access:https://www.mdpi.com/2072-6694/13/22/5778

Internet

https://www.mdpi.com/2072-6694/13/22/5778

Similar Items